REVEAL: A phase I/II, open-label, multicenter, dose escalation and dose expansion study of NKTR-262 [TLR 7/8 agonist] plus NKTR-214 [CD122-biased agonist] with or without nivolumab (nivo) in patients (pts) with locally advanced or metastatic solid tumor malignancies
Adi Diab(Cleveland Clinic), Sandra P. D’Angelo(Memorial Sloan Kettering Cancer Center), Jonathan Zalevsky(Nektar Therapeutics (United States)), Ute Hoch(University of Arizona), Mario Q. Marcondes(Nektar Therapeutics (United States)), J. Zhang(Nektar Therapeutics (United States)), Erkut Borazanci(HonorHealth), Mary Tagliaferri(Nektar Therapeutics (United States)), Werner Rubas(University of California, San Francisco), Anthony P. Conley(The University of Texas MD Anderson Cancer Center), Saul Kivimäe(Nektar Therapeutics (United States))
Cited by 7
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
|Journal of Clinical Oncology|2015|1.1k
β-Arrestin–Dependent Endocytosis of Proteinase-Activated Receptor 2 Is Required for Intracellular Targeting of Activated Erk1/2
|The Journal of Cell Biology|2000|816
Enhanced antibody half-life improves in vivo activity
|Nature Biotechnology|2010|654
JNK and Tumor Necrosis Factor-α Mediate Free Fatty Acid-induced Insulin Resistance in 3T3-L1 Adipocytes
|Journal of Biological Chemistry|2005|403